Pathology and pharmacology of lung cancer, stomach cancer and colorectal cancer

Zihan Hu

doi:10.62051/72f3za41

Authors

Zihan Hu

DOI:

https://doi.org/10.62051/72f3za41

Keywords:

Cancer; Pathology; Pharmacology.

Abstract

Cancer, a term that strikes fear and concern in the hearts of millions around the globe, stands as one of the most formidable diseases of our time. It has been responsible for an alarming escalation in the number of fatalities annually, casting a dark shadow over the world’s health statistics. The insidious nature of cancer is further highlighted by the fact that it is no longer confined to the elderly, and it is increasingly affecting younger individuals, defying traditional age-related patterns. However, there is still no cure for cancer, so the development of cancer drugs is particularly important. When looking to the future, the relentless march of technological advancement offers a beacon of hope. With each breakthrough in fields such as genomics, immunotherapy, and nanotechnology, the possibility of defeating cancer is getting closer and closer. This research will cover the history of cancer, introduce three different types of cancer, their pathology and pharmacology.

Downloads

Download data is not yet available.

References

[1] S. Nussbaumer, P. Bonnabry, J. L. Veuthey, et al. Analysis of anticancer drugs: a review, Talanta 85 (2011) 2265 - 2289.

[2] A. Sudhakar, History of cancer, ancient and modern treatment methods, Journal of cancer science & therapy 1 (2009) 1.

[3] V. C. Broaddus, J. D. Ernst, T. E. King Jr, et al. (Eds.). Murray & Nadel's textbook of respiratory medicine, Elsevier Health Sciences, 2021, pp. 1018 - 1028.

[4] W. D. Travis, E. Brambilla, H. K. Müller-Hermelink, et al. Pathology and genetics of tumours of the lung, pleura, thymus, and heart. WHO Classification of Tumours, 3rd Edition, 10 (2004) 344.

[5] W. C. Dempke, T. Suto, M. Reck, Targeted therapies for non-small cell lung cancer, Lung cancer 67 (2010) 257 - 274.

[6] W. C. Dempke, V. Heinemann, Resistance to EGF-R (erbB-1) and VEGF-R modulating agents, European journal of cancer 45 (2009) 1117 - 1128.

[7] S. Nagini, Carcinoma of the stomach: A review of epidemiology, pathogenesis, molecular genetics and chemoprevention, World journal of gastrointestinal oncology 4 (2012) 156.

[8] M. Sarbia, K. F. Becker, H. Höfler, Pathology of upper gastrointestinal malignancies, In Seminars in oncology 2004 pp. 465 - 475.

[9] G. D. Lewis Phillips, G. Li, D. L. Dugger, et al. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody–cytotoxic drug conjugate, Cancer research 68 (2008) 9280 - 9290.

[10] K. Shitara, H. Iwata, S. Takahashi, et al. Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive gastric cancer: a dose-expansion, phase 1 study, The Lancet Oncology 20 (2019) 827 - 836.

[11] F. Carreiró, A. M. Oliveira, A. Neves, et al. Polymeric nanoparticles: Production, characterization, toxicology and ecotoxicology, Molecules. 25 (2020) 3731.

[12] L. Tamayo, H. Palza, J. Bejarano, et al. Polymer composites with metal nanoparticles: synthesis, properties, and applications, In Polymer composites with functionalized nanoparticles 2019 pp. 249 - 286.

[13] R. L. Siegel, K. D. Miller, A. Jemal, Cancer statistics, 2018, CA: a cancer journal for clinicians 68 (2018) 7 - 30.

[14] F. Bray, J. Ferlay, I. Soerjomataram, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA: a cancer journal for clinicians 68 (2018) 394 - 424.

[15] D. Treanor, P. Quirke, Pathology of colorectal cancer, Clinical oncology 19 (2007) 769 - 776.

[16] C. C. Compton, Colorectal carcinoma: diagnostic, prognostic, and molecular features, Modern Pathology 16 (2003) 376 - 388.

[17] J. Jessurun, M. Romero-Guadarrama, J. C. Manivel, Medullary adenocarcinoma of the colon: clinicopathologic study of 11 cases, Human pathology 30 (1999) 843 - 848.

[18] H. N. Mo, P. Liu, Targeting MET in cancer therapy, Chronic diseases and translational medicine 3 (2017) 148 - 153.

[19] Y. H. Xie, Y. X. Chen, J. Y. Fang, Comprehensive review of targeted therapy for colorectal cancer, Signal transduction and targeted therapy 5 (2020) 22.

[20] C. H. Tsai, C. H. Teng, Y. T. Tu, et al. HAI-2 suppresses the invasive growth and metastasis of prostate cancer through regulation of matriptase, Oncogene 33 (2014) 4643 - 4652.